Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Transfus Apher Sci ; 30(3): 197-203, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15172624

ABSTRACT

BACKGROUND: In transfusional setting introduction of nucleic amplification technique (NAT) for HBV-DNA, HCV-RNA and HIV-RNA in biological qualification of blood units suggest some problems. At first the opportunity to operate on mini-pool, at second the need to store the samples at +4 degrees C. The authors therefore have tried to estimate the impact of these conditions on the operativity of NAT testing in the transfusional setting. METHODS: The following parameters has been estimated: distribution of viral-load in untreated subjects, stability of nucleic acids during storage at +4 degrees C, stability of nucleic acids after repeated cycles of freezing and defrosting, robustness of the test to the cross-contamination, definition of the detection-limit (95%). Quantitative tests has been performed by using the following kits: Cobas Amplicor HBV Monitor, Cobas Amplicor HCV Monitor, Cobas Amplicor HIV Monitor; the qualitative tests has been performed by using the following kits: Ampliscreen HBV, Ampliscreen HCV 2,0, Ampliscreen HIV 1,5 all supplied by Roche Molecular System (Brancburg, NJ). RESULTS: Viral load in untreated subjects showed wide variation for HBV, HCV and HIV. HBV has been demonstrated much stable to the conservation +4 degrees C also until 168 h while for HCV and HIV a greater decrease of the viral-load was observed. For all and three virus the conservation to +4 degrees C until 72 h does not seem to involve meaningful fall in the viral-load. A remarkable reduction of the viral-load has been observed after five cycles of freezing and defrosting. All the tests showed a good robustness to cross-contamination. The detection-limit (95%) was 8 U/ml for HBV, 21 U/ml for HCV and 27 copy/ml for HIV. CONCLUSIONS: Samples for NAT testing, can be stored until 72 h to +4 degrees C without appreciable lowering of the viral-load. Repeated cycles of changes of state should be avoided. The tests showed a good robustness to cross-contamination. NAT tests for biological qualification of blood units had a minimal sensibility around 50 (copy/unit/ml). In our experience the detection-limit (95%) was 21 U/ml for HCV, 27 copies/ml for HIV, 8 U/ml for HBV. The availability of NAT test for HBV-DNA, HCV-RNA e HIV-RNA, sensitive and reliable, together with epidemiological data, suggest the opportunity to place side by side, in the biological qualification of the blood units, to add the tests for HBV-DNA and HIV-RNA to the test for HCV-RNA mandatory by low, in Italy in the biological qualification of blood units.


Subject(s)
Blood Preservation/methods , DNA, Viral/isolation & purification , Nucleic Acids/blood , RNA Stability , RNA, Viral/isolation & purification , Refrigeration/statistics & numerical data , HIV Infections/blood , HIV Infections/prevention & control , HIV-1/genetics , HIV-1/isolation & purification , Hepacivirus/genetics , Hepacivirus/isolation & purification , Hepatitis B/blood , Hepatitis B/prevention & control , Hepatitis B virus/genetics , Hepatitis B virus/isolation & purification , Hepatitis C/blood , Hepatitis C/prevention & control , Humans , Refrigeration/standards , Sensitivity and Specificity , Temperature , Time Factors , Viral Load/statistics & numerical data
2.
Minerva Ginecol ; 54(4): 333-8, 2002 Aug.
Article in Italian | MEDLINE | ID: mdl-12114866

ABSTRACT

BACKGROUND: This study report the results obtained in a retrospective analysis of the foetal-maternal alloimmunizations observed from 1993 to 1999 in the South-East area of the Venice province. METHODS: The data concerning 17,000 pregnancy observed in this area from 1993-1999 have been collected. For each pregnancy data concerning maternal ABO, Rh, Kk and IAT as well as foetal ABO, Rh, Kk and DAT were available. Further data (mainly antibodies concentration and specificity) were available if a foetal-maternal alloimmunization was detected and if transfusional support was given after the birth. RESULTS: The authors observed 465 alloimmunizations (prevalence 2.7%): 381 (82%) of these were due to an ABO foetal-maternal incompatibility, 23 due to D incompatibility and the other 61 due to other blood groups antigens. Only 6 cases needed transfusional support: 5 exchange transfusion (a patient needed 2 exchanges) and a delayed transfusion. CONCLUSIONS: Foetal-maternal alloimmunizations are today a rare but not exceptional event (about 3% of pregnancy), the great majority of these alloimmunizations are due to an ABO incompatibility. Despite the prevention of alloimmunization in D negative women by using Rh immune globulin, anti-D alloimmunization is still observed. A great number of other blood groups antigens are involved in foetal-maternal alloimmunization mainly within the Rh system (CcEe, etc.). In the authors' experience the great majority of foetal-maternal alloimmunizations were clinically silent, only 6 cases (1.3% of patients with a positive DAT) needed transfusional therapy.


Subject(s)
Erythroblastosis, Fetal/epidemiology , Pregnancy Complications, Hematologic/epidemiology , Rh Isoimmunization/epidemiology , ABO Blood-Group System/blood , Blood Group Incompatibility/immunology , Coombs Test , Erythroblastosis, Fetal/blood , Female , Fetal Blood/immunology , Fetomaternal Transfusion/immunology , Humans , Infant, Newborn , Maternal-Fetal Exchange , Pregnancy , Pregnancy Complications, Hematologic/blood , Retrospective Studies , Rh Isoimmunization/blood , Rho(D) Immune Globulin/therapeutic use
3.
J Viral Hepat ; 7(4): 283-6, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10886537

ABSTRACT

One of the major issues in nucleic acid testing is how to store blood samples to obtain reliable results. We therefore studied hepatitis C virus (HCV) RNA concentration in samples after storage at +4 degrees C or freezing and thawing. Six HCV RNA-positive, untreated subjects were studied. Blood samples were collected from these subjects in plasma preparation tubes. The HCV RNA concentration was analysed after storage at +4 degrees C for 168 h or after five freeze-thaw cycles. For HCV RNA quantification we used a qualitative and a quantitative commercial test. After 168 h of storage at +4 degrees C, the HCV RNA concentration was similar to that observed at time-point 0 (5.025 log vs 5.492 log). In one sample we observed a significant fall in HCV RNA concentration. After five freeze-thaw cycles, the HCV RNA concentration was lower than that observed at time-point 0 (4.454 log vs 5.492 log) and in four samples we observed a significant fall in HCV RNA concentration. Our data suggest that HCV RNA is stable in whole blood samples stored at +4 degrees C for 168 h. Based on our results, we conclude that the standard procedures for transport of blood samples (at room temperature for a maximum of 5 h) and storage schedules (+4 degrees C for a maximum of 48 h) can be maintained without compromising the quality of results.


Subject(s)
Hepacivirus/isolation & purification , RNA, Viral/blood , Blood Donors , Blood Preservation/methods , Blood Transfusion , Cold Temperature , Drug Stability , Evaluation Studies as Topic , Freezing , Hepatitis C/diagnosis , Hepatitis C/prevention & control , Hepatitis C/transmission , Humans , In Vitro Techniques
4.
Immunol Lett ; 16(1): 71-3, 1987 Oct.
Article in English | MEDLINE | ID: mdl-2962931

ABSTRACT

We have used 4B4 and 2H4 monoclonal antibodies in conjunction with OKT 4 to quantify T cell subsets in lymph node suspensions from human immunodeficiency virus (HIV) positive subjects with lymphadenopathy syndrome. The data indicate that the reduced OKT 4:OKT 8 ratio was due to a depletion of the OKT 4+ 4B4+ subset. In contrast, there were no differences compared to reactive controls, considering the OKT8+ subpopulation. These alterations may be related to the immunological deficiency associated with HIV infection.


Subject(s)
Acquired Immunodeficiency Syndrome/immunology , Lymph Nodes/immunology , T-Lymphocytes, Helper-Inducer/immunology , T-Lymphocytes, Regulatory/immunology , Antibodies, Monoclonal , Antigens, Differentiation, T-Lymphocyte/immunology , Biopsy , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...